Randomized, double-blind 6-month comparison of olanzapine and quetiapine in patients with schizophrenia or schizoaffective disorder with prominent negative symptoms and poor functioning

Journal of Clinical Psychopharmacology

Volumn 26, Issue 5, 2006, Pages 453-461

  Kinon, Bruce J ^a   Noordsy, Douglas L ^b   Liu Seifert, Hong ^a   Gulliver, Angela H ^a   Ascher Svanum, Haya ^a   Kollack Walker, Sara ^a  

^a ELI LILLY AND COMPANY   (United States)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OLANZAPINE; QUETIAPINE;

ADULT; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SIDE EFFECT; SOCIAL ASPECT; SOCIAL PSYCHOLOGY; SOMNOLENCE; TREATMENT OUTCOME; WEIGHT GAIN;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DIBENZOTHIAZEPINES; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; PATIENT COMPLIANCE; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; QUALITY OF LIFE; RESEARCH DESIGN; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SEVERITY OF ILLNESS INDEX; SOCIAL ADJUSTMENT; TREATMENT OUTCOME;

EID: 33748743350     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000236658.16286.25     Document Type: Article

References (57)

1. Mueser KT, Bellack AS, Morrison RL, et al. Social competence in schizophrenia: premorbid adjustment, social skill, and domains of functioning. J Psychiatr Res. 1990;24:51-63.
2. Breier A, Schreiber JL, Dyer J, et al. National Institute of Mental Health longitudinal study of chronic schizophrenia. Prognosis and predictors of outcome. Arch Gen Psychiatry. 1991;48:239-246.
3. Solinski S, Jackson HJ, Bell RC. Prediction of employability in schizophrenic patients. Schizophr Res. 1992;7:141-148.
4. Bell MD, Lysaker PH. Psychiatric symptoms and work performance among persons with severe mental illness. Psychiatr Serv. 1995;46:508-510.
5. Lysaker P, Bell M. Negative symptoms and vocational impairment in schizophrenia: repeated measurements of work performance over six months. Acta Psychiatr Scand. 1995;91:205-208.
6. Ho BC, Nopoulos P, Flaum M, et al. Two-year outcome in first-episode schizophrenia: predictive value of symptoms for quality of life. Am J Psychiatry. 1998;155:1196-1201.
7. Milev P, Ho BC, Arndt S, et al. Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first-episode study with 7-year follow-up. Am J Psychiatry. 2005;162:495-506.
8. Moller HJ. Management of the negative symptoms of schizophrenia: new treatment options. CNS Drugs. 2003;17:793-823.
9. Tandon R. Quetiapine has a direct effect on the negative symptoms of schizophrenia. Hum Psychopharmacol. 2004;19:559-563.
10. Tollefson GD, Sanger TM. Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine. Am J Psychiatry. 1997;154:466-474.
11. Moller HJ, Muller H, Borison RL, et al. A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients. A re-evaluation of the North American risperidone study. Eur Arch Psychiatry Clin Neurosci. 1995;245:45-49.
12. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry. 2003;60:553-564.
13. Leucht S, Pitschel-Walz G, Abraham D, et al. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr Res. 1999;35:1-68.
14. Schulz SC, Thomson R, Brecher M. The efficacy of quetiapine vs haloperidol and placebo: a meta-analytic study of efficacy. Schizophr Res. 2003;62:1-12.
15. Andreasen NC. Negative symptoms in schizophrenia. Definition and reliability. Arch Gen Psychiatry. 1982;39:784-788.
16. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261-276.
17. Guy W. ECDEU Assessment Manual for Psychopharmacology, Revised (Publication ADM 76-338). Rockville, MD: US Dept of Health, Education, and Welfare; 1976:218-222.
18. Addington D, Addington J, Maticka-Tyndale E, et al. Reliability and validity of a depression rating scale for schizophrenics. Schizophr Res. 1992;6:201-208.
19. Drake RE, Osher FC, Wallach MA. Alcohol use and abuse in schizophrenia. A prospective community study. J Nerv Ment Dis. 1989;177:408-414.
20. Drake RE, Osher FC, Noordsy DL, et al. Diagnosis of alcohol use disorders in schizophrenia. Schizophr Bull. 1990;16:57-67.
21. Bartels SJ, Drake RE, Wallach MA. Long-term course of substance use disorders among patients with severe mental illness. Psychiatr Serv. 1995;46:248-251.
22. Heinrichs DW, Hanlon TE, Carpenter WT Jr. The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull. 1984;10:388-398.
23. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl. 1970;212:11-19.
24. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989;154:672-676.
25. Glick ID, Marder SR. Long-term maintenance therapy with quetiapine versus haloperidol decanoate in patients with schizophrenia or schizoaffective disorder. J Clin Psychiatry. 2005;66:638-641.
26. Kirkpatrick B, Kopelowicz A, Buchanan RW, et al. Assessing the efficacy of treatments for the deficit syndrome of schizophrenia. Neuropsychopharmacology. 2000;22:303-310.
27. Kirkpatrick B, Buchanan RW, Breier A, et al. Case identification and stability of the deficit syndrome of schizophrenia. Psychiatry Res. 1993;47:47-56.
28. Kirkpatrick B, Buchanan RW, McKenney PD, et al. The Schedule for the Deficit syndrome: an instrument for research in schizophrenia. Psychiatry Res. 1989;30:119-123.
29. Montes JM, Ciudad A, Gascon J, et al. Safety, effectiveness, and quality of life of olanzapine in first-episode schizophrenia: a naturalistic study. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27:667-674.
30. Sacristan JA, Gomez JC, Montejo AL, et al. Doses of olanzapine, risperidone, and haloperidol used in clinical practice: results of a prospective pharmacoepidemiologic study. EFESO Study Group. Estudio Farmacoepidemiologico en la Esquizofrenia con Olanzapina. Clin Ther. 2000;22:583-599.
31. Noordsy DL, O'Keefe C. Effectiveness of combining atypical antipsychotics and psychosocial rehabilitation in a community mental health center setting. J Clin Psychiatry. 1999;60(suppl 19):47-51. discussion 52-3.
32. Noordsy DL, O'Keefe C, Mueser KT, et al. Six-month outcomes for patients who switched to olanzapine treatment. Psychiatr Serv. 2001;52:501-507.
33. Hamilton SH, Revicki DA, Genduso LA, et al. Olanzapine versus placebo and haloperidol: quality of life and efficacy results of the North American double-blind trial. Neuropsychopharmacology. 1998;18:41-49.
34. Revicki DA, Genduso LA, Hamilton SH, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: quality of life and clinical outcomes of a randomized clinical trial. Qual Life Res. 1999;8:417-426.
35. Hamilton SH, Edgell ET, Revicki DA, et al. Functional outcomes in schizophrenia: a comparison of olanzapine and haloperidol in a European sample. Int Clin Psychopharmacol. 2000;15:245-255.
36. Giner J, Bobes J, Cervera S, et al. Impact of olanzapine on quality of life of patients with schizophrenia: one-year follow-up with the Seville Quality of Life Questionnaire. Actas Esp Psiquiatr. 2004;32:1-7.
37. Corrigan PW, Reinke RR, Landsberger SA, et al. The effects of atypical antipsychotic medications on psychosocial outcomes. Schizophr Res. 2003;63:97-101.
38. Srisurapanont M, Maneeton B, Maneeton N. Quetiapine for schizophrenia. Cochrane Database Syst Rev. 2004:CD000967.
39. Voruganti L, Cortese L, Owyeumi L, et al. Switching from conventional to novel antipsychotic drugs: results of a prospective naturalistic study. Schizophr Res. 2002;57:201-208.
40. Velligan DI, Prihoda TJ, Sui D, et al. The effectiveness of quetiapine versus conventional antipsychotics in improving cognitive and functional outcomes in standard treatment settings. J Clin Psychiatry. 2003;64:524-531.
41. Pencer A, Addington J, Addington D. Outcome of a first episode of psychosis in adolescence: a 2-year follow-up. Psychiatry Res. 2005;133:35-43.
42. Racenstein JM, Harrow M, Reed R, et al. The relationship between positive symptoms and instrumental work functioning in schizophrenia: a 10 year follow-up study. Schizophr Res. 2002;56:95-103.
43. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209-1223.
44. Dossenbach M, Erol A, el Mahfoud KM, et al. Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol. J Clin Psychiatry. 2004;65:312-321.
45. Dossenbach M, Arango-Davila C, Silva IH, et al. Response and relapse in patients with schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol: 12-month follow-up of the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) Study. J Clin Psychiatry. 2005;66:1021-1030.
46. Dunayevich E, Zhao F, Ascher-Svanum H, et al. Longer time to all-cause antipsychotic discontinuation is associated with better schizophrenia treatment outcomes. Biol Psychiatry. 2005;57:107S.
47. Anderson JE, O'Donnell BF, McCarley RW, et al. Progressive changes in schizophrenia: do they exist and what do they mean? Restor Neurol Neurosci. 1998;12:175-184.
48. Perkins DO. Predictors of noncompliance in patients with schizophrenia. J Clin Psychiatry. 2002;63:1121-1128.
49. Basson BR, Kinon BJ, Taylor CC, et al. Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone. J Clin Psychiatry. 2001;62:231-238.
50. Mori K, Nagao M, Yamashita H, et al. Effect of switching to atypical antipsychotics on memory in patients with chronic schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2004;28:659-665.
51. Zoccali R, Muscatello MR, Torre DL, et al. Lack of a pharmacokinetic interaction between mirtazapine and the newer antipsychotics clozapine, risperidone and olanzapine in patients with chronic schizophrenia. Pharmacol Res. 2003;48:411-414.
52. Gureje O, Miles W, Keks N, et al. Olanzapine vs risperidone in the management of schizophrenia: a randomized double-blind trial in Australia and New Zealand. Schizophr Res. 2003;61:303-314.
53. Kasper S, Brecher M, Fitton L, et al. Maintenance of long-term efficacy and safety of quetiapine in the open-label treatment of schizophrenia. Int Clin Psychopharmacol. 2004;19:281-289.
54. Cutler AJ, Goldstein JM, Tumas JA. Dosing and switching strategies for quetiapine fumarate. Clin Ther. 2002;24:209-222.
55. Smith MA, McCoy R, Hamer-Maansson J, et al. Rapid dose escalation with quetiapine: a pilot study. J Clin Psychopharmacol. 2005;25:331-335.
56. Nagy J. Effectiveness of quetiapine up to 1600 mg/day: short-term results with 14-month follow-up. Eur Neuropsychopharmacol. 2003;13(suppl 4):S340.
57. Davis JM, Chen N. Dose response and dose equivalence of antipsychotics. J Clin Psychopharmacol. 2004;24:192-208.